Safety and Pharmacokinetic Study of Jin Fu Kang In Combination With Docetaxel for Patients With Previously Treated Non-Small Cell Lung Cancer
Jin Fu Kang is a herbal medicine specially developed in China for the treatment of lung
cancer. It is based on a traditional medicine that is widely used and appears to be safe.
Although clinical trials in China suggest that Jin Fu Kang may be of benefit, it has never
been researched in patients with lung cancer in the United States. As such, its risks and
benefits are not fully understood.
The scientific aims are to determine the toxicity of Jin Fu Kang/docetaxel combination
treatment in patients with non-small cell lung cancer, to determine whether Jin Fu Kang
alters the pharmacokinetics of docetaxel and to provide preliminary efficacy and survival
data for Jin Fu Kang/docetaxel combination treatment in patients with non-small cell lung
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the toxicity of Jin Fu Kang / docetaxel combination treatment in patients with previously treated non-small cell lung cancer.
Naiyer A Rizvi, M.D
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|